Key Points for Decision Makers {#FPar1}
==============================

In Thailand, pharmaceutical care is a more recent and relatively simple approach to improve adherence to pulmonary tuberculosis (TB) treatment compared with home visit and modified directly observed therapy (DOT).Our findings shed light on the potential role of the clinical pharmacist in pulmonary TB outpatient services. Timely pharmacist-led patient education for every outpatient visit and pharmacist-provided telephone consultation required less healthcare resources.

Introduction {#Sec1}
============

According to the World Health Organization (WHO), Thailand is one of the 22 high-burden countries for tuberculosis (TB) with nearly 160,000 TB patients, and 11,900 TB-related deaths in 2014 \[[@CR1]\]. In 2014, the domestic funding for the Thai National TB program exceeded the contributions from international donors, with only 11% of the budget funded internationally \[[@CR1]\]. Most TB patients seek healthcare in public hospitals where TB diagnosis and treatment are covered by Thai public insurance schemes. Healthcare for people with TB-related symptoms usually starts with initial clinical consultation, diagnostic tests, and non-TB specific medications \[[@CR2], [@CR3]\]. The TB diagnostic process may require multiple visits to complete the tests and meet healthcare professionals for medical diagnosis \[[@CR4], [@CR5]\]. Before TB diagnosis and during TB treatment, healthcare may include hospitalization, treatment of adverse drug reactions (ADRs), and augmenting nutrition.

Although WHO recommends directly observed therapy (DOT) to promote adherence for pulmonary TB patients \[[@CR6]\], it is not feasible to widely implement DOT for TB control in Thailand, especially in the large hospitals due to healthcare resource constraints. Therefore, the national TB program adopts a daily dose regimen whereby patients take the TB medications themselves at home and visit a health center or a district hospital at least once a month to refill their prescriptions. Hospitals adopt different supervision approaches, including home visit and modified DOT (see below for details). Recently, pharmaceutical care, a pharmacist-led patient education program, was adopted in a tertiary hospital to improve adherence to TB treatment.

According to our previous retrospective cohort study \[[@CR7]\], all three TB treatment adherence enhancement strategies that are currently adopted in Thai referral hospitals provided very similar TB treatment success rates and were associated with high rates of success and exceeded the WHO treatment success target of 85%. However, there is little evidence on the economic implications associated with these strategies. Healthcare resource uses and costs have been recognized as important pieces of information to inform health policy making, especially in allocating public funds in resource-constrained contexts. Therefore, this study is a cost-minimization analysis, from a healthcare sector perspective, inclusive of out-of-pocket expenditures. The objective of this study is to estimate and compare direct costs associated with pharmaceutical care compared with home visit and modified DOT in pulmonary TB patients in Thailand.

Methods {#Sec2}
=======

Data Sources {#Sec3}
------------

This was a retrospective study based on patient medical records, TB registration records, and the billing database at three public referral hospitals in Songkhla province, southern Thailand: Songklanagarind hospital, Hatyai hospital, and Songkhla hospital, where pharmaceutical care, home visit, and modified DOT, respectively, have been adopted. Songklanagarind hospital is an 850-bed teaching hospital affiliated to the Prince of Songkla University (PSU). Hatyai hospital (700-bed, tertiary care) and Songkhla hospital (480-bed, secondary care) are the main provincial referral hospitals under the Ministry of Public Health. This study was approved by the Research Ethics Board at each of the participating hospitals.

Pharmaceutical care provides pharmacist-led patient education at every outpatient visit and telephone consultation at any time via mobile phone regarding disease, medications, possible ADRs, and lifestyle modifications. The home visit approach provides regular home visit until treatment completion. The modified DOT provides direct observation, but only for the first 2 weeks of TB treatment, followed by regular home visit. The description of each of these TB treatment adherence enhancement strategies is shown in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of each treatment strategyServicesPharmaceutical careHome visitModified DOTOutpatient visits Who provides the services?Clinical pharmacistNurseNurse or pharmacist ActivitiesPharmacist-led patient education\
Monitoring and management of ADRs\
Identifying other drug-related problems\
Evaluation of treatment adherence\
Providing pharmacist's telephone consultationNurse-led patient education\
Monitoring and management of ADRs\
Evaluation treatment adherenceNurse- or pharmacist-led patient education\
Monitoring and management of ADRs\
Evaluation of treatment adherence Follow-up frequency^a^Days 0, 14, 60, 120, 180 or\
Days 0, 14, 60, 90 or 120, 150, 180Days 0, 14, (30), 60, 90, (120), 150, 180Days 0, 30, 60, 90, 150, 180Supervision activities Who provides the services?NoneNon-medical staffNon-medical staff ActivitiesNoneHome visit\
 Patients take medications by themselves at home with regular home visitDOT\
 Patients take medications under direct supervision\
Home visit\
 Patients take medications by themselves at home with regular home visit Visit scheduleNoneHome visit\
 Once a week in the first 2 months\
 Once a month until treatment completionDaily DOT\
 First 2 weeks of treatment\
Home visit\
 Twice a week for the first month\
 Once a week in the second month\
 Twice a month until treatment completion*ADRs* adverse drug reactions, *DOT* directly observed therapy^a^ The outpatient follow-up frequency depends on patient's individual condition and the occurrence of ADRs

Patient Eligibility Criteria {#Sec4}
----------------------------

The eligibility criteria for this cost analysis included age ≥18 years, pulmonary TB confirmed by a physician and classified bacteriologically as smear-positive or smear-negative, TB treatment started between October 2010 and September 2013, and a treatment period of ≥2 months in the study hospitals.

Recommended TB Treatment in Thailand {#Sec5}
------------------------------------

First-line anti-TB medications include isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E), and streptomycin (S). The standard treatment regimen for drug-susceptible pulmonary TB is a daily combination of four first-line antibiotics (2HRZE/4HR) for at least 6 months divided into two treatment phases: an intensive phase (first 2 months) and a continuous phase (the remaining 4 months). Re-treatment patients are treated with an 8-month re-treatment regimen (2HRZES/1HRZE/5HRE), while patients with multi-drug-resistant tuberculosis (MDR-TB) require second-line agents (at least 20 months) as recommended by WHO \[[@CR1]\].

Healthcare Resource Uses and Costs {#Sec6}
----------------------------------

The cost analysis was conducted from a healthcare sector perspective inclusive of out-of-pocket expenditures, which included direct healthcare costs to the public payer and to the patients. Costs were estimated separately for the pre-TB treatment period (from illness onset to TB diagnosis) and the TB treatment period (from the start to the completion of TB treatment). These costs were considered as costs associated with TB diagnosis and treatment if patients were diagnosed with at least one of the two ICD-10 codes for respiratory TB (A15 or A16). There are a few other relevant healthcare resource uses (e.g., treatment of ADRs, hospitalization, nutrition, and others). Therefore, costs incurred with some ICD-10 codes needed to be investigated concurrently with other information (e.g., type of outpatient service, laboratory investigation, patient's medical record, and TB registration record) before they were determined to be associated with TB diagnosis and treatment (see Appendix Table 1 in the electronic supplementary material).

The Thai population has been covered under one of the three public insurance schemes: the civil servant medical benefits scheme (CSMBS), the social security scheme (SSS), and the universal coverage scheme (UC), all funded through general tax revenues \[[@CR8]\]. The CSMBS covers government employees, pensioners, and their dependents in which insured persons can access, free of charge, medical services at all government hospitals. The SSS is for private employees who can freely access medical services at a contracted hospital. Every Thai citizen not covered under the CSMBS or the SSS is covered by the UC, but needs to pay all medical costs out of pocket if they seek healthcare services outside their primary residential area. As of 2015, 75% of the Thai population is covered under the UC \[[@CR9]\].

Following the Thai Comptroller General's Department's healthcare service classification, we categorized direct costs into seven categories: medications, laboratory investigation and pathology, diagnostic radiology, medical services, supervision activities, hospitalization, and miscellaneous costs. Except medications costs, which were calculated using a mark-up method, unit costs of services in all remaining categories were set by factoring the costs related to labor, material, capital, overhead, and future development costs. Direct costs for each healthcare service in the hospitals were calculated by multiplying the natural units for the services with the corresponding unit costs. Costs associated with implementing supervision activities (i.e., the home visit at Hatyai hospital and the modified DOT at Songkhla hospital) were estimated separately as non-medical staff must be hired to provide these services. In addition to the salary paid from hospital, the global fund paid these staff 600 baht for each smear-positive drug-susceptible patient who successfully completed treatment, and 300 baht monthly for supervising each MDR-TB patient.

Methods for handling missing information varied depended on the type of data. Missing resource use items for laboratory investigation and diagnostic radiology were replaced by using each hospital's standard procedures for pulmonary TB care, while missing quantities of medication used were estimated from patients' drug regimen.

Out-of-pocket expenditures not covered by patients' health insurance were also retrieved from hospital billing databases. These costs included copayment, non-essential drugs (NEDs), food nutrition, and non-covered medical costs (e.g., costs incurred to patients when accessing services provided outside their district).

All costs were calculated in Thai currency (Thai baht), adjusted with the cumulative inflation rate from the year of data collection to 2015 \[[@CR10]\], and then converted to international dollars using the 2015 purchasing power parity (PPP) conversion factor of private consumption (LCU per international \$) \[[@CR11]\].

Statistical Analysis {#Sec7}
--------------------

Descriptive analyses of demographic data were conducted to describe the patient population included in the cost analyses. Categorical variables were analyzed using a Chi squared test, unless expected cell counts were low, in which case Fisher's exact test was used. Mean and standard deviation (SD) was calculated for continuous variables and differences were evaluated using analysis of variance (ANOVA).

For the cost data, measures other than the arithmetic mean (e.g., median costs, log transformed costs) do not provide information about the costs of treating all patients, which is more informative for healthcare policy decisions \[[@CR12]\]. Therefore, we reported arithmetic mean costs with SD. Since the Shapiro--Wilk test indicated that all costs data were positively skewed, a nonparametric bootstrap technique was used to compare arithmetic mean costs and to derive the 95% confidence intervals (CI) \[[@CR13]\].

Differences in the total costs between treatment strategies adjusted for baseline demographics were investigated by generalized linear models (GLMs) \[[@CR14], [@CR15]\]. The performance of GLMs with the inverse Gaussian and gamma distribution were investigated. Two different link functions (e.g., the identity and log link) were compared. Covariates act additively in the identity-link model, and multiplicatively in the log-link model \[[@CR14]\]. Thus, GLMs using an identity link estimate the difference in costs, while those using a log link estimate a ratio. The model included six baseline covariates of treatment strategy, sex, age, habitat, health insurance, and HIV status. Model performance was assessed by using normal probability plots (P--P plots), normal quantile plots (Q--Q plots) of deviance residuals \[[@CR14], [@CR16]\], and Akaike information criterion (AIC) \[[@CR14], [@CR17]\]. Smaller AIC values indicate better-fitting models; differences of ten or more in AIC indicate that the better-fitting model should be strongly preferred \[[@CR14]\]. Normal plots were assessed visually. When points fall close to the reference line this indicates that model assumptions are suitable \[[@CR14], [@CR16], [@CR18]\]. Data analyses were performed using SPSS software \[[@CR19]\].

Results {#Sec8}
=======

Between October 2010 and September 2013, 2444 adult patients started pulmonary TB treatment in the three study hospitals and 1398 patients met our eligibility criteria and were included in the analysis. There were 315 patients on pharmaceutical care, 559 on home visit, and 524 on modified DOT (Fig. [1](#Fig1){ref-type="fig"}). Baseline characteristics and complications in TB treatment of the included patients are described in Table [2](#Tab2){ref-type="table"}.Fig. 1Flowchart of study participants. *Asterisk* indicates 'Transferred out' are patients who have started the TB treatment, then relocated to new address. Therefore, they were transferred to new district. Transferred patients for whom the treatment outcome was unknown were excluded. *Dagger* indicates patients were categorized as 'other' by using the available medical record and their provided information. 'Other cases' are all cases that do not fit the definitions of 'new', 'previously treated' (e.g., relapse, treatment after failure, treatment after default), and 'transfer in', such as patients for whom it is not known whether they have been previously treated; who were previously treated but with unknown treatment outcome; who have returned to treatment with smear-negative pulmonary TB or bacteriologically negative extrapulmonary TB. *DOT* directly observed therapy, *PSU* Prince of Songkla University, *TB* tuberculosis Table 2Baseline characteristics and complications in tuberculosis treatment of 1398 participants categorized by treatment strategyVariables1398 cases*p* valuePharmaceutical care (*n* = 315)\
*n* (%)Home visit (*n* = 559)\
*n* (%)Modified DOT (*n* = 524)\
*n* (%)Baseline characteristics Sex  Male192 (61.0)388 (69.4)342 (65.3)0.037  Female123 (39.0)171 (30.6)182 (34.7) Mean age (SD), years49.90 (18.42)44.85 (15.83)45.38 (16.56)\<0.001^a^ Age group, years  18--2434 (10.8)52 (9.3)44 (8.4)\<0.001  25--3446 (14.6)114 (20.4)110 (21.0)  35--4439 (12.4)129 (23.1)127 (24.2)  45--5466 (21.0)117 (20.9)96 (18.3)  ≥55130 (41.3)147 (26.3)147 (28.1) Live in Songkhla  Yes178 (56.5)559 (100)524 (100)\<0.001  No137 (43.5)00 Health insurance^b^  UC95 (30.2)375 (67.1)352 (67.2)\<0.001  CSMBS132 (41.9)32 (5.7)61 (11.6)  SSS12 (3.8)113 (20.2)92 (17.6)  Not covered by public health insurance76 (24.1)39 (7.0)19 (3.6) HIV status  Yes10 (3.2)99 (17.7)100 (19.0)\<0.001  No256 (81.3)445 (79.6)420 (80.2)  Unknown49 (15.6)15 (2.7)4 (0.8) Co-morbidity  Yes157 (49.8)154 (27.5)140 (26.7)\<0.001  No158 (50.2)405 (72.5)384 (73.3) Sputum smear  Positive271 (86.0)455 (79.6)348 (66.4)\<0.001  Negative44 (14.0)114 (20.4)176 (33.6) Registration  New288 (91.4)539 (96.4)473 (90.3)\<0.001  Re-treatment27 (8.6)20 (3.6)51 (9.7)Complications in TB treatment Develop MDR-TB  Yes5 (1.6)2 (0.0 4)1 (0.2)0.019^c^  No308 (97.8)557 (99.6)522 (99.6)  MDR-TB at baseline2 (0.6)01 (0.02) Re-challenge anti-TB drug use  Yes27 (8.6)63 (11.3)43 (8.2)0.186  No288 (91.4)496 (88.7)481 (91.8) Hepatotoxicity with anti-TB drugs  Yes19 (6.0)40 (7.2)26 (5.0)0.320  No396 (94.0)519 (92.8)498 (95.0) Adverse events  No adverse events146 (46.3)389 (69.6)429 (81.9)\<0.001  Severe28 (8.9)63 (11.3)45 (8.6)  Mild141 (44.8)107 (19.1)50 (9.5) Hospitalization for TB  Yes7 (2.2)127 (22.7)145 (27.7)\<0.001  No308 (97.8)432 (77.3)379 (72.3)Variables were analyzed using Chi squared test, unless expected cell counts were low, in which case Fisher's exact test was used*ANOVA* analysis of variance, *DOT* directly observed therapy, *MDR*-*TB* multi-drug-resistant tuberculosis, *TB* tuberculosis^a^ One-way ANOVA^b^ Thai population have been covered under one of the three public insurance schemes, namely the civil servant medical benefits scheme (*CSMBS*), the social security scheme (*SSS*), and the universal coverage (*UC*)^c^ Fisher's Exact test

Forty-three percent of patients in the pharmaceutical care group traveled from a neighboring province to seek TB care at the study hospital, while all patients in the home visit and the modified DOT groups lived in Songkhla province. Sixty-seven percent of patients each in the home visit and the modified DOT groups were covered by the UC, compared with only 30.2% in the pharmaceutical care group. The pharmaceutical care group had more patients who accessed healthcare that was not covered by their public insurance (24.1, 7.0, and 3.6% for patients receiving pharmaceutical care, home visit, and modified DOT, respectively). Only 2% of patients in the pharmaceutical care group were hospitalized, while 22.7 and 27.7% were hospitalized in home visit and modified DOT groups, respectively. Durations of the intensive phase were 2.5, 2.7, and 2.5 months while the continuous phase took 4.6, 5.2, and 4.0 months on average in the patients receiving pharmaceutical care, home visit, and modified DOT, respectively (Table [3](#Tab3){ref-type="table"}).Table 3Drug regimen and treatment duration of 1398 included patients categorized by treatment strategyVariable1398 cases*p* valuePharmaceutical care (*n* = 315)Home visit (*n* = 559)Modified DOT (*n* = 524)Initial treatment regimen, *n* (%) 2HRZE/4HR309 (98.1)546 (97.7)517 (98.7)0.164^a^ 2HRZES/1HRZE/5HRE4 (1.3)13 (2.3)6 (1.1) Others2 (0.6)01 (0.2)Treatment duration, mean (SD) Duration of intensive phase, months2.5 (1.4)2.7 (1.1)2.5 (0.99)0.001^b^ Duration of continuation phase, months4.6 (2.2)5.2 (3.1)4.0 (1.4)\<0.001^b^*ANOVA* analysis of variance, *DOT* directly observed therapy, *E* ethambutol, *H* isoniazid, *R* rifampicin, *S* streptomycin, *Z* pyrazinamide^a^ Fisher's Exact test^b^ One-way ANOVA

Healthcare Resource Uses and Direct Costs Incurred Before and During TB Treatments {#Sec9}
----------------------------------------------------------------------------------

In the pre-TB treatment period, the primary healthcare resource use in the patients receiving pharmaceutical care was laboratory investigation \$100.55 (95% CI 94.82--106.46); while for those receiving home visit and modified DOT, the main resource use was hospitalization (\$137.64, 95% CI 100.92--180.73; and \$137.77, 95% CI 111.45--164.91, respectively).

During TB treatment period, the main resource use for the patients receiving pharmaceutical care was medications (\$269.33, 95% CI 227.40--324.52). For patients receiving home visit and modified DOT, the main health resource uses included medications, supervision activities, and hospitalization (Table [4](#Tab4){ref-type="table"}).Table 4Mean direct costs per patient by cost category (in 2015 international dollars) incurred to health services and to 1398 patients before and during TB treatment categorized by treatment strategyServicesPharmaceutical care (*n* = 315)Home visit (*n* = 559)Modified DOT (*n* = 524)Arithmetic mean (SD)95% CIArithmetic mean (SD)95% CIArithmetic mean (SD)95% CIPre-TB treatment Medications2.51 (8.97)1.62--3.610.16 (1.39)0.06--0.281.96 (9.59)1.30--2.75 Laboratory investigation100.55 (52.57)94.82--106.4627.50 (25.21)25.55--29.6621.33 (27.86)18.75--23.79 Diagnostic radiology28.50 (62.65)22.51--35.5118.90 (41.47)15.71--22.7314.90 (40.21)12.19--18.31 Medical services10.47 (26.78)7.80--13.193.32 (2.28)3.14--3.525.26 (4.38)4.91--5.66 Miscellaneous costs0.46 (3.10)0.18--0.830.55 (1.12)0.46--0.650.04 (0.29)0.02--0.06 Hospitalization18.02 (218.66)2.53--43.98137.64 (502.38)100.92--180.73137.77 (348.95)111.45--164.91 Total costs160.51 (239.07)141.26--185.59188.08 (492.02)151.99--228.63181.27 (345.40)150.99--210.55 Costs to health services108.23 (128.51)94.11--122.86180.30 (491.39)144.04--220.70160.16 (311.25)134.71--187.11 Costs to patients52.28 (227.35)34.73--77.777.79 (57.64)4.01--12.7621.11 (165.22)9.53--37.15TB treatment Medications269.33 (431.09)227.40--324.52281.57 (213.33)266.33--297.36212.66 (158.38)202.55--225.86 Laboratory investigation154.53 (133.98)140.97--171.08107.58 (70.64)102.12--113.33127.81 (104.53)119.40--137.27 Diagnostic radiology38.47 (43.85)34.46--43.2822.46 (15.39)21.28--23.8026.66 (30.21)24.38--29.30 Medical services27.55 (31.48)24.45--31.2130.50 (40.51)27.72--33.9836.11 (38.74)33.23--39.64 Supervision activities0218.23 (178.05)205.47--232.03217.67 (182.09)201.83--233.64 Miscellaneous costs2.60 (16.38)1.22--4.574.08 (8.38)3.48--4.701.93 (4.26)1.60--2.29 Hospitalization42.42 (624.54)0--113.08221.65 (1237.85)135.60--326-58133.03 (557.95)90.32--181.95 Total costs534.91 (879.99)451.33--650.14886.07 (1286.99)789.66--995.53755.86 (656.35)700.76--817.97 Costs to health services411.73 (863.56)330.99--521.12840.09 (1270.06)745.59--948.39727.63 (644.72)675.15--789.90 Costs to patients123.18 (327.19)88.56--165.5445.98 (275.80)27.58--70.0728.22 (112.17)19.13--38.91Total Total costs695.41 (904.88)609.34--813.101074.16 (1465.81)964.49--1211.83937.12 (768.00)872.79--1009.90 Total costs to health services519.96 (883.05)437.31--625.581020.39 (1455.52)911.13--1154.11887.79 (747.26)824.28--955.91 Total costs to patients175.45(432.88)130.26--230.4853.77 (298.17)33.25--79.4449.33 (219.93)34.03--69.30Medical services included medical supplies, special diagnostics, medical equipment, operations services, outpatient services, and physical therapy. Miscellaneous costs included food solution, ambulatory care, copayments, other non-medical services, and special physician fees*DOT* directly observed therapy, *TB* tuberculosis

The mean direct costs per patient to the public healthcare payer were \$519.96 (95% CI 437.31--625.58), \$1020.39 (95% CI 911.13--1154.11), and \$887.79 (95% CI 824.28--955.91) for those receiving pharmaceutical care, home visit, and modified DOT, respectively (Table [4](#Tab4){ref-type="table"}). The mean costs to patients were \$175.45 (95% CI 130.26--230.48), \$53.77 (95% CI 33.25--79.44), and \$49.33 (95% CI 34.03--69.30) for those receiving pharmaceutical care, home visit, and modified DOT, respectively (Table [4](#Tab4){ref-type="table"}). The mean total direct costs per patient were \$695.41 (95% CI 609.34--813.10), \$1074.16 (95% CI 964.49--1211.83), and \$937.12 (95% CI 872.79--1009.90) for those receiving pharmaceutical care, home visit, and modified DOT, respectively (Table [4](#Tab4){ref-type="table"}). There was significant difference in mean total costs when comparing pharmaceutical care with either home visit or modified DOT.

The main expenses for pharmaceutical care were medications and laboratory investigation (39.0 and 36.7% of total costs, respectively). On the other hand, the three largest contributors to total costs in home visit and modified DOT were hospitalizations, medications, and supervision activities (33.4, 26.2, and 20.3% in home visit; 28.9, 22.9, and 23.2% in modified DOT) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Breakdown of total costs incurred for each treatment strategy: **a** pharmaceutical care, **b** home visit, and **c** modified directly observed therapy (*DOT*). Percentages are proportion of respective sub-component cost out of the total costs

The differences in mean total costs between treatment strategies when adjusted for baseline characteristics were investigated by the GLMs. The P--P and Q--Q plots were similar for models with the same distribution regardless of the link function (Fig. [3](#Fig3){ref-type="fig"}). The model performance assessment using the AICs (Table [5](#Tab5){ref-type="table"}) and graphical analyses indicated that the GLMs with the inverse Gaussian distribution and identity link were the best model. After adjustment for baseline characteristics, pharmaceutical care was associated with statistically significant lower direct costs compared with home visit (−\$354.95, 95% CI −285.67 to −424.23) and modified DOT (−\$264.61, 95% CI −198.76 to −330.46) (Table [6](#Tab6){ref-type="table"}).Fig. 3Normal probability plots (P--P plots) of deviance residuals for the GLMs: **a** gamma family and identity link; **b** inverse Gaussian family and identity link. Normal quantile plots (Q--Q plots) of deviance residuals for the GLMs: **c** gamma family and identity link; **d** inverse Gaussian family and identity link. Similar plots are obtained with a log link. *GLMs* generalized linear models Table 5Comparison of GLMs with two different types of distributions and either identity or log link for models including six baseline covariatesDistributionsLink functionsAICGammaIdentity21,220.19Log21,223.12Inverse GaussianIdentity20,720.10Log20,724.58*AIC* Akaike information criterion, *GLMs* generalized linear models Table 6Difference in mean total direct costs between the specified group compared with reference group when impact of differences in baseline characteristics was adjusted by GLMs with inverse Gaussian distribution and the identity linkVariableDifference in mean costs95% CI*p* valueSupervision strategy Home visit354.95285.67 to 424.23**\<0.001** Modified DOT264.61198.76 to 330.46**\<0.001**Gender Male−5.39−54.73 to 43.940.830Age group, years 25--34123.5244.88 to 202.16**0.002** 35--44121.9442.06 to 201.83**0.003** 45--54206.00124.45 to 287.56**\<0.001** \>55216.28136.55 to 296.02**\<0.001** Local−148.43−232.50 to −64.35**0.001**Health insurance CSMBS18.58−55.37 to 92.530.622 SSS−98.71−168.63 to 28.79**0.006** Not covered by public health insurance40.14−40.19 to 120.460.327HIV status Yes780.04605.67 to 954.41**\<0.001** Unknown41.30−63.77 to 146.360.441Statistically significant differences in mean total direct costs are highlighted in boldReferences used in each category were supervision strategy (pharmaceutical care), gender (female), age group (18--24 years), habitat (non-local), health insurance (UC), HIV status (no). Significance for all statistical analyses was *p* \< 0.05*CSMBS* Civil Servant Medical Benefits Scheme, *GLMs* generalized linear models, *SSS* Social Security Scheme, *UC* Universal Coverage

Discussion {#Sec10}
==========

Our previous study has shown that TB treatment success rates for pharmaceutical care are very similar to those for home visit or modified DOT \[[@CR7]\]. This cost analysis shows that the pharmaceutical care approach is a relatively simple strategy that requires less healthcare resources and costs compared with the other two approaches. The main health resource uses in the pharmaceutical care group were medications and laboratory investigation. In contrast, the supervision activities were one of the three main resource uses for both home visit and modified DOT groups.

Differences in patient characteristics across treatment strategies may have explained the difference in some healthcare resource uses. The pharmaceutical care group had lower hospitalization costs because almost half (43.5%) of patients traveled from a neighboring province seeking TB care at the study hospital. This implies that their illness might not be severe. If these patients had any severe respiratory condition or required emergency admission, they would have accessed local hospitals. In contrast, the home visit and the modified DOT groups had higher hospitalization costs because these two hospitals are the main provincial referral hospitals under the Ministry of Public Health and generally have higher numbers of TB patients as well as more severe cases. These hospitals are the first choice for local patients who need free and urgent TB care.

The large variation in costs observed in our study is consistent with a systematic review by Laurence et al. \[[@CR20]\]. They reported that the costs to healthcare providers varied widely across different and within country income-level groups. Hospitalization accounted for 74% of all provider-incurred costs for treating drug-susceptible TB in all country income groups, but only 12% in upper middle-income countries. They also reported that the mean outpatient costs were 12 times less than hospitalization costs. However, direct costs have reduced over time (between 1990 and 2015) due to the lower admission rates and more ambulatory care in many countries. These trends are supported by previous studies indicating that ambulatory care was clinically effective and cheaper than inpatient hospital care during the first 2 months (intensive phase) \[[@CR21], [@CR22]\]. The ambulatory model, therefore, has become the standard of TB care in high-burden countries \[[@CR23]\], including Thailand.

Obviously, patients in the pharmaceutical-care group paid 3-fold higher out-of-pocket costs for the TB treatments compared with those receiving home visit and modified DOT. Most of these expenses were direct healthcare costs incurred when patients accessed services outside their district. Apart from the issue of a hospital's location, the insurance policy is founded on the referral system. Patients in need of specialized treatment would be referred directly to the hospitals under the Ministry of Public Health. Since the study hospital is an academic tertiary hospital, a possible explanation for these patients' willingness to pay out of pocket may be that they had more confidence in the quality of care provided in this hospital.

In Thailand, the provision for home visit and modified DOT is funded by the Ministry of Public Health, in alignment with the WHO's recommended strategy and the global fund's incentives for patient supervision. Advantages of these supervisory activities are to provide close observation in patients' homes to check if patients have had any difficulty taking TB medications, and to ensure TB screening of the index patients' family members. In contrast, pharmaceutical care is more recent and differs from the WHO's recommended strategy, which emphasizes the importance of direct supervision in the initial 2 months of treatment \[[@CR24]\]. Our findings shed light on the potential role of the clinical pharmacist in TB outpatient services. Timely pharmacist-led patient education for every outpatient visit and pharmacist-provided telephone consultation required less healthcare resources compared with the other two approaches. A larger scale, prospective study is warranted to generate more robust evidence to support Thai policy making about the most efficient uses of limited resources to fight TB in this developing country.

Our study has limitations. The data used in the analysis came from a retrospective hospital database review. A number of patients had missing information and the approach to handling missing information depended on the type of data. Since this study abstracted costs from hospital databases, only direct healthcare costs were included. In addition, a large proportion of the patients in the pharmaceutical care group came from other regions, the direct non-medical costs and indirect costs (income loss and productivity loss) incurred by them would be expected to be higher than those in the other two hospitals. Further research on the financial burden of TB borne by patients, and health-related quality of life associated with each strategy, was conducted for properly assessing these adherence improvement strategies.

Conclusion {#Sec11}
==========

After adjustment for baseline characteristics, pharmaceutical care was associated with lower direct costs compared with home visit and modified DOT.
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